<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508375</url>
  </required_header>
  <id_info>
    <org_study_id>2018-03</org_study_id>
    <secondary_id>2018-A00066-49</secondary_id>
    <nct_id>NCT03508375</nct_id>
  </id_info>
  <brief_title>Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis</brief_title>
  <acronym>SCLEROLUNG</acronym>
  <official_title>Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic Scleroderma (SCS) is an autoimmune disease characterized by vascular involvement, a
      dysimmune condition, cutaneous and visceral fibrosis. Interstitial lung disease (ILD) affects
      75% of SSc patients and is the leading cause of death in SSc. No diagnostic or prognostic
      biomarkers of SSc-associated ILD have been validated to date. The search for such a serum
      biomarker is essential to assess the severity of these patients and to help the therapeutic
      management.

      We have shown that soluble fractalkine is elevated in SSc patients, especially in SSc
      patients with ILD. The fractalkine is both an endothelial adhesion molecule and a chemokine
      that binds to the CX3CR1 receptor expressed by immune populations. It would thus reflect the
      vasculopathy and inflammation that lead to the fibrosing pulmonary involvement of this
      disease.

      Objectives and means: We aim to perform a low-risk interventional biomedical research which
      main objective is the quantitative evaluation of soluble fractalkine in SSc patients with ILD
      in comparison with SSc patients without ILD. This epidemiological, explanatory, analytical,
      single-center study will comprise three groups: 1 / SSc without ILD (control group in the
      context of SSc), 2/ SSc with ILD and 3/ patients with idiopathic pulmonary fibrosis (IPF)
      (control group of the ILD). Secondary objectives are evaluation of: 1 / fractalkine levels in
      the IPF, 2 / correlations between fractalkine levels and severity of ILD and of SSc disease
      over time, 3 / correlations between fractalkine and 2 other biomarkers: KL-6 (marker of
      pulmonary fibrosis) and soluble CD146 (sCD146, marker of vasculopathy), 4 / predictive values
      of the decline in lung function of these 3 markers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fractalkine levels</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Systemic Scleroderma</condition>
  <arm_group>
    <arm_group_label>SSc without ILD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SSc with ILD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with idiopathic pulmonary fibrosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>blood samples</description>
    <arm_group_label>SSc without ILD</arm_group_label>
    <arm_group_label>SSc with ILD</arm_group_label>
    <arm_group_label>patients with idiopathic pulmonary fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over the age of 18 with SSc with or without ILD with a medical follow up in
             AP-HM

          -  Patients, followed at AP-HM, with IPF

        Exclusion Criteria:

          -  Impossibility of taking blood

          -  Known diagnosis of respiratory disorders other than SSc-associated ILD and IPF

          -  An infection in progress

          -  An evolutive cancer

          -  Chemotherapy or radiation therapy in progress

          -  Minors

          -  Pregnant or lactating women

          -  Majors under guardianship

          -  People staying in a health or social facility

          -  People in emergency

          -  Non-beneficiaries of a social security scheme

          -  Persons deprived of their liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Audrey BENYAMINE</last_name>
    <email>audrey.benyamine@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>alexandra giuliani</last_name>
    <phone>0491382747</phone>
    <email>drci@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <state>BDR</state>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ALEXANDRA GIULIANI, DRCI</last_name>
      <phone>0491382747</phone>
      <email>drci@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>audrey benyamine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

